EFFECT OF ALCOHOL ON HEPATOCELLULAR CARCINOMA PROGRESSION IN VIVO
酒精对体内肝细胞癌进展的影响
基本信息
- 批准号:7470210
- 负责人:
- 金额:$ 16.16万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2008
- 资助国家:美国
- 起止时间:2008-09-20 至 2010-08-31
- 项目状态:已结题
- 来源:
- 关键词:AccountingAddressAdverse effectsAffectAflatoxinsAlcohol abuseAlcohol consumptionAlcoholsAlternative TherapiesAnimalsAntioxidantsBiochemical PathwayBiological AvailabilityBloodCYP2E1 geneCessation of lifeChemicalsChronicCicatrixCirrhosisClinical TrialsConsumptionControlled StudyDailyDataDevelopmentDiethylnitrosamineDiseaseEffectivenessEnvironmentEnzymesEthanolEthanol MetabolismEventFailureFutureGTP-Binding ProteinsGenerationsGonadal Steroid HormonesGrowthHealthcareHepaticHepatocyteHistologyHumanImmune responseImmunoblottingImmunohistochemistryIn VitroIncidenceInjection of therapeutic agentIntakeLaboratoriesLiverLiver CirrhosisLiver diseasesMalignant NeoplasmsMeasuresMediatingMetabolismMethionineMilk ThistleModelingMonitorMusNatureNeonatalOperative Surgical ProceduresOrganOxidative StressPathway interactionsPatientsPlantsPolymerase Chain ReactionPredisposing FactorPrimary carcinoma of the liver cellsRangeRateReactive Oxygen SpeciesRecording of previous eventsReportingResearchResearch PersonnelRewardsRiskRisk FactorsRodent ModelRoleSignal PathwaySignal TransductionSignal Transduction PathwaySocietiesStimulation of Cell ProliferationSystemTestingTherapeutic AgentsTimeTissuesToxinTranslationsViralWeekalcohol abuse therapyalcohol effectaldehyde dehydrogenasesbasecarcinogenesiscell transformationchronic alcohol ingestionclinically relevantdaydietary supplementsdrinking waterenzyme activityfeedingflavanoidhuman diseasein vivointerestlaser capture microdissectionmalemortalitynovelprotective effectsilibinintumortumor progression
项目摘要
DESCRIPTION (provided by applicant): The incidence of hepatocellular carcinoma (HCC) is increasing dramatically in the US and globally, and accounts for more than 600,000 deaths/year. Cirrhosis of the liver, whether chemically or virally induced, is the major predisposing factor to the development of HCC. Chronic alcohol consumption has been identified as a significant risk factor in patients developing cirrhosis and progression to HCC, both in its own right and as a synergistic factor following viral or chemical insult. Advances in our understanding of the cellular and biochemical pathways affected following alcohol ingestion have identified ethanol metabolism (and associated reactive oxygen species (ROS) generation/oxidative stress) as a major factor in mediating the deleterious effects of alcohol in the liver and other organs. These findings have led to the proposed use of systemic antioxidants to inhibit the development and progression of several hepatic diseases including HCC. These studies have led to the emergence of S-adenosyl methionine (SAMe) as a potential therapeutic agent. While efficacious in rodent models, there is increasing concern regarding its effectiveness in human clinical trials. For several millennia natural antioxidants have been used in the treatment of liver disease. Despite their over-the-counter availability relatively little is known about their efficacy and mechanisms of action. Previous studies by our laboratory demonstrate a central role for G-proteins in mediating mitogenesis in HCC in vitro. Furthermore, treatment with alcohol enhances these pro-mitogenic pathways. While considerable research has identified important events during hepatic cell transformation in the setting of chronic alcohol consumption, relatively little is known about the effects of alcohol on the rate of HCC progression in livers predisposed to tumor formation. The current proposal hypothesizes that chronic alcohol consumption increases the rate and incidence of foci development and HCC progression. To test this hypothesis studies will be performed using in vivo murine models of progressive foci development and HCC progression in animals undergoing chronic alcohol consumption. In addition this proposal will address the mechanistic effects by which silibinin, a commonly used flavanoid derived from the milk thistle plant, acts to inhibit the rate of tumor progression in a clinically relevant model of HCC in the absence and presence of chronic alcohol intake. Specifically, these studies will focus on identifying the role of specific, pro-mitogenic signaling cascades demonstrated to be important in HCC proliferation that are affected by alcohol treatment in vitro. Given the widespread use and abuse of alcohol in society, and concerns regarding the efficacy of current therapeutic agents for the treatment of HCC, we believe it is imperative to explore alternative approaches. While widely available, and anecdotally effective, little is understood about the mechanisms of action of plant- derived antioxidants in the treatment of hepatic disease.
描述(由申请人提供):肝细胞癌(HCC)的发病率在美国和全球范围内急剧增加,每年死亡人数超过60万。无论是化学还是病毒诱导的肝硬化,都是HCC发生的主要诱发因素。慢性饮酒已被确定为发展为肝硬化和进展为HCC的患者的重要危险因素,无论是其本身还是病毒或化学损伤后的协同因素。我们对酒精摄入后影响的细胞和生化途径的理解取得了进展,已经确定乙醇代谢(以及相关的活性氧(ROS)生成/氧化应激)是介导酒精对肝脏和其他器官有害影响的主要因素。这些发现导致建议使用全身性抗氧化剂来抑制包括HCC在内的几种肝脏疾病的发生和进展。这些研究导致s -腺苷型蛋氨酸(SAMe)作为一种潜在的治疗剂出现。虽然在啮齿动物模型中有效,但其在人体临床试验中的有效性越来越受到关注。几千年来,天然抗氧化剂一直被用于治疗肝病。尽管它们的非处方可用性相对较少,但人们对它们的功效和作用机制知之甚少。我们实验室先前的研究表明,g蛋白在体外介导肝癌细胞有丝分裂发生中发挥了核心作用。此外,酒精治疗增强了这些促有丝分裂途径。虽然相当多的研究已经确定了慢性饮酒背景下肝细胞转化过程中的重要事件,但对于酒精对易形成肿瘤的肝脏中HCC进展速度的影响,我们所知相对较少。目前的建议假设长期饮酒会增加灶发展和HCC进展的速度和发生率。为了验证这一假设,研究将在长期饮酒的动物体内进行渐进式病灶发展和HCC进展的小鼠模型。此外,本研究还将探讨水飞蓟宾(一种从水飞蓟植物中提取的常用类黄酮)在没有和存在慢性酒精摄入的HCC临床相关模型中抑制肿瘤进展速率的机制作用。具体来说,这些研究将集中于鉴定特异性的促有丝分裂信号级联的作用,这些信号级联在体外酒精治疗影响的HCC增殖中被证明是重要的。鉴于酒精在社会上的广泛使用和滥用,以及对当前治疗HCC药物疗效的担忧,我们认为有必要探索替代方法。虽然植物源性抗氧化剂广泛使用,而且疗效显著,但人们对其治疗肝病的作用机制知之甚少。
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
IAIN HUGH MCKILLOP其他文献
IAIN HUGH MCKILLOP的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('IAIN HUGH MCKILLOP', 18)}}的其他基金
FABP4 Released from Steatotic Hepatocytes in Alcoholic Liver Disease Enhances Hepatic Tumor Progression
酒精性肝病中脂肪肝细胞释放的 FABP4 促进肝肿瘤进展
- 批准号:
10380190 - 财政年份:2021
- 资助金额:
$ 16.16万 - 项目类别:
FABP4 Released from Steatotic Hepatocytes in Alcoholic Liver Disease Enhances Hepatic Tumor Progression
酒精性肝病中脂肪肝细胞释放的 FABP4 促进肝肿瘤进展
- 批准号:
10491369 - 财政年份:2021
- 资助金额:
$ 16.16万 - 项目类别:
EFFECT OF ALCOHOL ON HEPATOCELLULAR CARCINOMA PROGRESSION IN VIVO
酒精对体内肝细胞癌进展的影响
- 批准号:
7689374 - 财政年份:2008
- 资助金额:
$ 16.16万 - 项目类别:
REGULATION OF BENIGN AND MALIGNANT HEPATOCYTE GROWTH
良性和恶性肝细胞生长的调节
- 批准号:
6790510 - 财政年份:2002
- 资助金额:
$ 16.16万 - 项目类别:
REGULATION OF BENIGN AND MALIGNANT HEPATOCYTE GROWTH
良性和恶性肝细胞生长的调节
- 批准号:
6931028 - 财政年份:2002
- 资助金额:
$ 16.16万 - 项目类别:
REGULATION OF BENIGN AND MALIGNANT HEPATOCYTE GROWTH
良性和恶性肝细胞生长的调节
- 批准号:
6541474 - 财政年份:2002
- 资助金额:
$ 16.16万 - 项目类别:
REGULATION OF BENIGN AND MALIGNANT HEPATOCYTE GROWTH
良性和恶性肝细胞生长的调节
- 批准号:
6655596 - 财政年份:2002
- 资助金额:
$ 16.16万 - 项目类别:
G PROTEIN REGULATION IN HEPATOCELLULAR CARCINOMA
肝细胞癌中 G 蛋白的调节
- 批准号:
6342104 - 财政年份:2001
- 资助金额:
$ 16.16万 - 项目类别:
ROLE OF ETHANOL IN HEPATOCELLULAR CARCINOMA PROGRESSION
乙醇在肝细胞癌进展中的作用
- 批准号:
6509393 - 财政年份:2001
- 资助金额:
$ 16.16万 - 项目类别:
ROLE OF ETHANOL IN HEPATOCELLULAR CARCINOMA PROGRESSION
乙醇在肝细胞癌进展中的作用
- 批准号:
6327287 - 财政年份:2001
- 资助金额:
$ 16.16万 - 项目类别:
相似海外基金
Rational design of rapidly translatable, highly antigenic and novel recombinant immunogens to address deficiencies of current snakebite treatments
合理设计可快速翻译、高抗原性和新型重组免疫原,以解决当前蛇咬伤治疗的缺陷
- 批准号:
MR/S03398X/2 - 财政年份:2024
- 资助金额:
$ 16.16万 - 项目类别:
Fellowship
Re-thinking drug nanocrystals as highly loaded vectors to address key unmet therapeutic challenges
重新思考药物纳米晶体作为高负载载体以解决关键的未满足的治疗挑战
- 批准号:
EP/Y001486/1 - 财政年份:2024
- 资助金额:
$ 16.16万 - 项目类别:
Research Grant
CAREER: FEAST (Food Ecosystems And circularity for Sustainable Transformation) framework to address Hidden Hunger
职业:FEAST(食品生态系统和可持续转型循环)框架解决隐性饥饿
- 批准号:
2338423 - 财政年份:2024
- 资助金额:
$ 16.16万 - 项目类别:
Continuing Grant
Metrology to address ion suppression in multimodal mass spectrometry imaging with application in oncology
计量学解决多模态质谱成像中的离子抑制问题及其在肿瘤学中的应用
- 批准号:
MR/X03657X/1 - 财政年份:2024
- 资助金额:
$ 16.16万 - 项目类别:
Fellowship
CRII: SHF: A Novel Address Translation Architecture for Virtualized Clouds
CRII:SHF:一种用于虚拟化云的新型地址转换架构
- 批准号:
2348066 - 财政年份:2024
- 资助金额:
$ 16.16万 - 项目类别:
Standard Grant
BIORETS: Convergence Research Experiences for Teachers in Synthetic and Systems Biology to Address Challenges in Food, Health, Energy, and Environment
BIORETS:合成和系统生物学教师的融合研究经验,以应对食品、健康、能源和环境方面的挑战
- 批准号:
2341402 - 财政年份:2024
- 资助金额:
$ 16.16万 - 项目类别:
Standard Grant
The Abundance Project: Enhancing Cultural & Green Inclusion in Social Prescribing in Southwest London to Address Ethnic Inequalities in Mental Health
丰富项目:增强文化
- 批准号:
AH/Z505481/1 - 财政年份:2024
- 资助金额:
$ 16.16万 - 项目类别:
Research Grant
ERAMET - Ecosystem for rapid adoption of modelling and simulation METhods to address regulatory needs in the development of orphan and paediatric medicines
ERAMET - 快速采用建模和模拟方法的生态系统,以满足孤儿药和儿科药物开发中的监管需求
- 批准号:
10107647 - 财政年份:2024
- 资助金额:
$ 16.16万 - 项目类别:
EU-Funded
Ecosystem for rapid adoption of modelling and simulation METhods to address regulatory needs in the development of orphan and paediatric medicines
快速采用建模和模拟方法的生态系统,以满足孤儿药和儿科药物开发中的监管需求
- 批准号:
10106221 - 财政年份:2024
- 资助金额:
$ 16.16万 - 项目类别:
EU-Funded
Recite: Building Research by Communities to Address Inequities through Expression
背诵:社区开展研究,通过表达解决不平等问题
- 批准号:
AH/Z505341/1 - 财政年份:2024
- 资助金额:
$ 16.16万 - 项目类别:
Research Grant














{{item.name}}会员




